Basic Principles of Drug Discovery and Development, Third Edition presents a unique overview of the drug discovery and development program not available elsewhere. Each chapter provides sufficient technical details on the topics covered so that non-experts will have the tools and information necessary to interact and exchange information with colleagues across the entire spectrum of the drug discovery and development process. The drug discovery and development process involves individuals and teams with a wide array of expertise ranging from basic sciences (medicinal chemistry, biology) to applied science (pharmacology, pharmacokinetics, clinical sciences) to business driven fields (regulatory affairs, intellectual property experts, marketing specialists).

The success or failure of a program focused on bringing a new medication to market often depends on clear communication between individuals and teams with vastly different expertise. As a result, it is critical that experts in one aspect of drug discovery and development (e.g., medicinal chemists) have a working understanding of the wide range of disciplines that take part in the overall process.

Key Features

• Provides a clear explanation of how the pharmaceutical industry works, as well as the complete drug discovery process, from obtaining a lead, to testing the bioactivity, to producing the drug, and protecting the intellectual property
• Includes a new chapter on the discovery and development of biologics (antibodies proteins, antibody/receptor complexes, antibody drug conjugates), a growing and important area of the pharmaceutical industry landscape
• Features a new section on formulations, including a discussion of IV formulations suitable for human clinical trials, as well as the application of nanotechnology and the use of transdermal patch technology for drug delivery
• Includes new case studies with additional modern examples of drug discovery using high through-put screening, fragment-based drug design, and computational chemistry, as well as studies on the development of biologics